BUSINESS INSIGHTS

TriMas Announces Two New Acquisitions

TriMas | December 14, 2021

TriMas Announces Two New Acquisitions
TriMas announced that it has recently signed agreements to acquire Omega Plastics to be added to TriMas Packaging, and TFI Aerospace  to be added to TriMas Aerospace.

Omega, located in Clinton Township, Michigan, specializes in manufacturing custom components and devices for drug delivery, diagnostic and orthopedic medical applications, as well as components for industrial applications. Omega leverages its advanced in-house tool making capabilities, ISO13485-certified injection molding facility and ISO Class 8 clean room to provide its customers a faster product development cycle, from prototype development, testing and validation, to short and medium run production and assembly. Omega is an approved vendor to several leading medical device companies, with a long track record of unparalleled service and quality. Omega currently operates as a private, family-owned company, and is expected to generate approximately $18 million in revenue in fiscal year 2021.

We are excited to announce the agreement between TriMas and Omega. We look forward to expanding Omega’s production capacity to benefit its customers’ longer-term needs, while also leveraging Omega’s advanced tool making capabilities to add rapid prototyping to enhance TriMas Packaging’s speed-to-market advantage on innovation and new product designs. The addition of Omega further expands our Pharmaceutical & Nutraceutical product offerings into additional medical applications, which we believe is an attractive market for long-term growth.”

Thomas Amato, President and Chief Executive Officer of TriMas

Located near Toronto, Canada, TFI is a leading manufacturer and supplier of specialty fasteners used in a variety of applications, predominantly for the aerospace end market. TFI currently operates as a private, family-owned company, and is expected to generate approximately $6 million in revenue in fiscal year 2021.

“In addition to expanding TriMas Packaging through the acquisition of Omega, we are also pleased to announce the acquisition of TFI,” Amato continued. “This acquisition will further expand TriMas Aerospace’s fastener product lines with the addition of complimentary niche products that have an exciting growth trajectory resulting from TFI’s new program wins and the overall aerospace market recovery. We anticipate TFI’s customers will benefit from the added innovation and manufacturing depth offered by TriMas Aerospace, while TriMas Aerospace’s customers will enjoy additional product offerings.”

Amato continued, “We continue to execute on our core strategy of augmenting our growth through bolt-on acquisitions by leveraging our strong cash generation. After closing these two acquisitions, we expect our net leverage ratio to remain below 2.0x, providing ample capacity to execute on additional bolt-on acquisitions while also returning capital to shareholders through dividends and share buybacks.”

TriMas expects to close on Omega by the end of the year, and closed on TFI simultaneously with signing.

“We look forward to welcoming both Omega and TFI to the TriMas family of businesses,” concluded Amato.

About TriMas
TriMas is a global manufacturer and provider of products for customers primarily in the consumer products, aerospace and industrial markets, with approximately 3,300 dedicated employees in 11 countries. We provide customers with a wide range of innovative and quality product solutions through our market-leading businesses. Our TriMas family of businesses has strong brand names in the markets served, and operates under a common set of values and strategic priorities under the TriMas Business Model. TriMas is publicly traded on the NASDAQ under the ticker symbol “TRS,” and is headquartered in Bloomfield Hills, Michigan. 

Spotlight

PAREXEL helps position emerging Biopharmaceutical companies by providing them with advice and capabilities. We provide them with advice regarding clinical research strategies, regulatory strategies, as well as expedited approval pathways, to give a few examples.

Related News

Zealand Pharma strengthens executive team with new U.S. leadership

Globe newswire | June 15, 2020

Zealand Pharma, a biotechnology company changing lives with innovative peptide-based medicines, today announced the appointment of Frank Sanders as President of Zealand Pharma U.S. Frank will join Zealand on July 6, 2020. “I am pleased to welcome Frank Sanders to Zealand Pharma, and am confident that he will provide strong and experienced leadership for our U.S. organization,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Frank has more than 25 years of experience within commercial operations. He is well equipped to lead Zealand’s commercial operations to focus on growing existing sales of V-Go and to successfully launch four potential products beginning in 2021.” Frank has extensive experience in leading multidisciplinary operational teams to achieve successfully their growth strategies. He joins Zealand at a critical point in the company’s journey toward commercializing its proprietary products. Frank has worked in both start-up and established companies, where he has built, led and scaled organizations across sales, account management, marketing, pricing and contract strategy, operations, and patient support.

Read More

BUSINESS INSIGHTS

NanoPass and M2N enter strategic development & foundry agreement

NanoPass; M2N | December 23, 2021

NanoPass Technologies and Micro2Nano have reached an agreement to enter a strategic development and production relationship for the design and production of NanoPass's proprietary MEMS based microneedles. The aim of the collaboration is to strengthen the relationship between NanoPass and M2N and provide a basis for the continued growth of the two comaim of the collaboration is to strengthen the relationship between NanoPass and M2N panies while basing the new agreement on years of development and production collaboration. M2N has been an integral and inseparable part of Nanopass's development and manufacturing capabilities since 2007 and has been providing Nanopass with high quality foundry services, ingenuity and quick turn-around on development projects. NanoPass's proprietary technology platform is based on hollow, pyramid-shaped, microneedles. It is produced from silicon crystal using MEMS technology. The technology can be used for intradermal delivery of a wide range of injectables including vaccines and therapeutics, aesthetics, cosmetics and more. "M2N has been developing and manufacturing MEMS based microneedles with NanoPass for more than 14 years. It's an amazing thing considering the average lifespan of a company in recent years. During this long period of time, we have built a strong business relationship on the basis of trust. We are excited to provide high quality microneedles to NanoPass as a Prime Manufacturer and to support NanoPass in developing the new business applications as a Strategic R&D Partner." Kyuho Hwang, CEO of Micro2Nano Yotam Levin, MD, CEO of NanoPass, added, "M2N has been a trusted partner for over a decade and has been assisting NanoPass regularly with both its development projects and ongoing commercial production. M2N provides ongoing high-quality products, has a quick response time, and finds ingenious ways to solve complex problems. For us, trust is a key parameter for any partner, and M2N's organizational culture provides just the thing." About M2N M2N has been providing MEMS foundry service since its foundation in 2000. Profound experience and knowhow with MEMS processes enables M2N to co-work with multiple companies for developing new products and provide mass production services based on MEMS technology. Additionally, M2N has developed its own product line including MEMS probe cards for semiconductor wafer testing and MEMS sensors. About NanoPass NanoPass is a pioneer in the development and commercialization of microneedle-based delivery platforms for aesthetics, vaccines and more. MicronJet®600 is FDA 510k cleared, CE marked and has regulatory approval in Russia, Brazil, South Korea, China and more. It is supported by extensive clinical data and approved for the delivery of any substance or drug under the surface of the skin that is approved for this delivery route.

Read More

PHARMA TECH

CareRx Applauds Ontario Ministry of Health's Pause of Planned Fee Changes

CareRx | January 18, 2021

CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of specialty pharmacy services to seniors, is pleased that the Ontario Ministry of Health has announced that it will pause for one year previously scheduled changes to long-term care pharmacy funding, which were scheduled to go into effect on April 1, 2021. Under certain amendments to the Ontario Drug Benefit Act that came into effect on January 1, 2020, the reimbursement model for long-term care pharmacies in Ontario was changed from a fee-for-service model to a fee-per-bed capitation model under which pharmacies receive a fixed professional fee for all pharmacy services provided to residents in long-term care homes. The fee for 2020, which was prescribed at $1,500, was scheduled to decline to $1,400 per bed serviced on April 1, 2021. The step-down in capitation has now been paused until April 1, 2022. "Long-term care homes and their staff have faced unprecedented challenges during COVID-19," said David Murphy, President and Chief Executive Officer of CareRx. "This pause will ensure that pharmacies like CareRx can continue to deliver the same exceptional partnership and service offering to long-term care homes and help alleviate the burden COVID-19 has placed on home staff. We want to thank Minister Elliott, Minister Fullerton and the Ontario Government for their ongoing dialogue and commitment to protecting the wellbeing of residents in long-term care." About CareRx Corporation CareRx is Canada's leading provider of specialty pharmacy services to seniors. We serve approximately 50,000 residents in over 900 seniors and other communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

Read More

Spotlight

PAREXEL helps position emerging Biopharmaceutical companies by providing them with advice and capabilities. We provide them with advice regarding clinical research strategies, regulatory strategies, as well as expedited approval pathways, to give a few examples.